Carbon monoxide - Hillhurst Biopharmaceuticals
Alternative Names: HBI 002Latest Information Update: 28 May 2025
At a glance
- Originator Hillhurst Biopharmaceuticals
- Class Anti-inflammatories; Inorganic carbon compounds; Small molecules
- Mechanism of Action Heme oxygenase 1 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Sickle cell anaemia
- No development reported Brain injuries; Delayed graft function; Parkinson's disease
Most Recent Events
- 28 May 2025 No recent reports of development identified for preclinical development in Parkinson's-disease in USA (PO)
- 08 May 2025 Hillhurst Biopharmaceuticals plans to initiate a phase IIa trial for Parkinson's Disease in early 2025
- 15 Feb 2025 Phase-II clinical trials in Sickle cell anaemia (In adolescents, In adults) in Panama (PO) (NCT06144749)